A Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

Trial Profile

A Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs INO 1400 (Primary) ; INO 9012 (Primary)
  • Indications Breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 15 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top